{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:20:31Z","timestamp":1790432431067,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["614739"],"award-info":[{"award-number":["614739"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI126296"],"award-info":[{"award-number":["R21AI126296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1171488"],"award-info":[{"award-number":["OPP1171488"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CNPq Research Productivity Fellowship","award":["302518\/2018-5"],"award-info":[{"award-number":["302518\/2018-5"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Over the past five years, as a public service to encourage and accelerate drug discovery for diseases of poverty, the Medicines for Malaria Venture (MMV) has released box sets of 400 compounds named the Malaria, Pathogen and Stasis Boxes. Here, we screened the Pathogen Box against the post-infective larvae (schistosomula) of <jats:italic>Schistosoma mansoni<\/jats:italic> using assays particular to the three contributing institutions, namely, the University of California San Diego (UCSD) in the USA, the Swiss Tropical and Public Health Institute (Swiss TPH) in Switzerland, and the Funda\u00e7\u00e3o Oswaldo Cruz (FIOCRUZ) in Brazil. With the same set of compounds, the goal was to determine the degree of inter-assay variability and identify a core set of active compounds common to all three assays. New drugs for schistosomiasis would be welcome given that current treatment and control strategies rely on chemotherapy with just one drug, praziquantel.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Both the UCSD and Swiss TPH assays utilize daily observational scoring methodologies over 72 h, whereas the FIOCRUZ assay employs XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide) at 72\u00a0h to measure viability as a function of NAD<jats:sup>+<\/jats:sup>\/NADH redox state. Raw and transformed data arising from each assay were assembled for comparative analysis.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For the UCSD and Swiss TPH assays, there was strong concordance of at least 87% in identifying active and inactive compounds on one or more of the three days. When all three assays were compared at 72\u00a0h, concordance remained a robust 74%. Further, robust\u00a0Pearson\u02bcs correlations (0.48\u20130.68) were measured between the assays. Of those actives at 72\u00a0h, the UCSD, Swiss TPH and FIOCRUZ assays identified 86, 103 and 66 compounds, respectively, of which 35 were common. Assay idiosyncrasies included the identification of unique compounds, the differential ability to identify known antischistosomal compounds and the concept that compounds of interest might include those that <jats:italic>increase<\/jats:italic> metabolic activity above baseline.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The inter-assay data generated were in good agreement, including with previously reported data. A common set of antischistosomal molecules for further exploration has been identified.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13071-019-3747-6","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:28:23Z","timestamp":1571804903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery"],"prefix":"10.1186","volume":"12","author":[{"given":"Martina","family":"Maccesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro H. N.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rian","family":"Pasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Montefusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Abagyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-3521","authenticated-orcid":false,"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina M.","family":"Mour\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor R.","family":"Caffrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"3747_CR1","unstructured":"WHO. Crossing the Billion. Preventive chemotherapy for neglected tropical diseases. Geneva: World Health Organization; 2017. \n                    http:\/\/www.who.int\/neglected_diseases\/resources\/9789240696471\/en\/\n                    \n                  . Accessed 5 Sept 2017."},{"key":"3747_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cbpa.2007.05.031","volume":"11","author":"CR Caffrey","year":"2007","unstructured":"Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol. 2007;11:433\u20139.","journal-title":"Curr Opin Chem Biol"},{"key":"3747_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-018-0013-8","volume":"4","author":"DP McManus","year":"2018","unstructured":"McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou X-N. Schistosomiasis. Nat Rev Dis Primer. 2018;4:13.","journal-title":"Nat Rev Dis Primer."},{"key":"3747_CR4","doi-asserted-by":"publisher","first-page":"675","DOI":"10.4155\/fmc.15.27","volume":"7","author":"CR Caffrey","year":"2015","unstructured":"Caffrey CR. Schistosomiasis and its treatment. Future Med Chem. 2015;7:675\u20136.","journal-title":"Future Med Chem."},{"key":"3747_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijpddr.2018.10.004","volume":"8","author":"AR Wolfe","year":"2018","unstructured":"Wolfe AR, Neitz RJ, Burlingame M, Suzuki BM, Lim KC, Scheideler M, et al. TPT sulfonate, a single, oral dose schistosomicidal prodrug: in vivo efficacy, disposition and metabolic profiling. Int J Parasitol Drugs Drug Resist. 2018;8:571\u201386.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"3747_CR6","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1371\/journal.pntd.0000478","volume":"3","author":"M-H Abdulla","year":"2009","unstructured":"Abdulla M-H, Ruelas DS, Wolff B, Snedecor J, Lim K-C, Xu F, et al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis. 2009;3:e478.","journal-title":"PLoS Negl Trop Dis"},{"key":"3747_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40364-016-0075-2","volume":"4","author":"EM Tekwu","year":"2016","unstructured":"Tekwu EM, Anyan WK, Boamah D, Baffour-Awuah KO, Keyetat Tekwu S, Penlap Beng V, et al. Mechanically produced schistosomula as a higher-throughput tools for phenotypic pre-screening in drug sensitivity assays: current research and future trends. Biomark Res. 2016;4:21.","journal-title":"Biomark Res."},{"key":"3747_CR8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41596-018-0101-y","volume":"14","author":"FC Lombardo","year":"2019","unstructured":"Lombardo FC, Pasche V, Panic G, Endriss Y, Keiser J. Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni. Nat Protoc. 2019;14:461\u201381.","journal-title":"Nat Protoc."},{"key":"3747_CR9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1093\/bioinformatics\/btu831","volume":"31","author":"D Asarnow","year":"2015","unstructured":"Asarnow D, Rojo-Arreola L, Suzuki BM, Caffrey CR, Singh R. The QDREC web server: determining dose-response characteristics of complex macroparasites in phenotypic drug screens. Bioinformatics. 2015;31:1515\u20138.","journal-title":"Bioinformatics."},{"key":"3747_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1186\/s13071-015-1233-3","volume":"8","author":"G Panic","year":"2015","unstructured":"Panic G, Flores D, Ingram-Sieber K, Keiser J. Fluorescence\/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays. Parasites Vectors. 2015;8:624.","journal-title":"Parasites Vectors."},{"key":"3747_CR11","doi-asserted-by":"publisher","first-page":"e1762","DOI":"10.1371\/journal.pntd.0001762","volume":"6","author":"RA Paveley","year":"2012","unstructured":"Paveley RA, Mansour NR, Hallyburton I, Bleicher LS, Benn AE, Mikic I, et al. Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis. 2012;6:e1762.","journal-title":"PLoS Negl Trop Dis"},{"key":"3747_CR12","doi-asserted-by":"publisher","first-page":"e1005763","DOI":"10.1371\/journal.ppat.1005763","volume":"12","author":"WCV Voorhis","year":"2016","unstructured":"Voorhis WCV, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, et al. Open source drug discovery with the Malaria Box compound collection for neglected diseases and beyond. PLOS Pathog. 2016;12:e1005763.","journal-title":"PLOS Pathog"},{"key":"3747_CR13","doi-asserted-by":"publisher","first-page":"e00379-17","DOI":"10.1128\/AAC.00379-17","volume":"61","author":"S Duffy","year":"2017","unstructured":"Duffy S, Sykes ML, Jones AJ, Shelper TB, Simpson M, Lang R, et al. Screening the Medicines for Malaria Venture Pathogen Box across multiple pathogens reclassifies starting points for open-source drug discovery. Antimicrob Agents Chemother. 2017;61:e00379-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"3747_CR14","doi-asserted-by":"publisher","first-page":"e2610","DOI":"10.1371\/journal.pntd.0002610","volume":"8","author":"K Ingram-Sieber","year":"2014","unstructured":"Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, et al. Orally active antischistosomal early leads identified from the open access Malaria Box. PLoS Negl Trop Dis. 2014;8:e2610.","journal-title":"PLoS Negl Trop Dis."},{"key":"3747_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1021\/acsinfecdis.8b00220","volume":"5","author":"V Pasche","year":"2019","unstructured":"Pasche V, Laleu B, Keiser J. Early antischistosomal leads identified from in vitro and in vivo screening of the medicines for Malaria Venture Pathogen Box. ACS Infect Dis. 2019;5:102\u201310.","journal-title":"ACS Infect Dis."},{"key":"3747_CR16","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s13071-018-2855-z","volume":"11","author":"V Pasche","year":"2018","unstructured":"Pasche V, Laleu B, Keiser J. Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni. Parasites Vectors. 2018;11:298.","journal-title":"Parasites Vectors"},{"key":"3747_CR17","doi-asserted-by":"publisher","first-page":"e850","DOI":"10.1371\/journal.pntd.0000850","volume":"4","author":"S Stefanic","year":"2010","unstructured":"\u0160tefani\u0107 S, Dvo\u0159\u00e1k J, Horn M, Braschi S, Sojka D, Ruelas DS, et al. RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. PLoS Negl Trop Dis. 2010;4:e850.","journal-title":"PLoS Negl Trop Dis"},{"key":"3747_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/0014-4894(74)90005-8","volume":"35","author":"DG Colley","year":"1974","unstructured":"Colley DG, Wikel SK. Schistosoma mansoni: simplified method for the production of schistosomules. Exp Parasitol. 1974;35:44\u201351.","journal-title":"Exp Parasitol."},{"key":"3747_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2307\/3280632","volume":"67","author":"P Basch","year":"1981","unstructured":"Basch P. Cultivation of Schistosoma mansoni in vitro. 1. Establishment of cultures from cercariae and development until pairing. J Parasitol. 1981;67:179\u201385.","journal-title":"J Parasitol."},{"key":"3747_CR20","doi-asserted-by":"publisher","first-page":"e0004356","DOI":"10.1371\/journal.pntd.0004356","volume":"10","author":"T Long","year":"2016","unstructured":"Long T, Neitz RJ, Beasley R, Kalyanaraman C, Suzuki BM, Jacobson MP, et al. Structure-bioactivity relationship for benzimidazole thiophene inhibitors of Polo-like kinase 1 (PLK1), a potential drug target in Schistosoma mansoni. PLoS Negl Trop Dis. 2016;10:e0004356.","journal-title":"PLoS Negl Trop Dis."},{"key":"3747_CR21","doi-asserted-by":"publisher","first-page":"e0005680","DOI":"10.1371\/journal.pntd.0005680","volume":"11","author":"T Long","year":"2017","unstructured":"Long T, Rojo-Arreola L, Shi D, El-Sakkary N, Jarnagin K, Rock F, et al. Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. PLoS Negl Trop Dis. 2017;11:e0005680.","journal-title":"PLoS Negl Trop Dis."},{"key":"3747_CR22","doi-asserted-by":"publisher","first-page":"e87594","DOI":"10.1371\/journal.pone.0087594","volume":"9","author":"L Rojo-Arreola","year":"2014","unstructured":"Rojo-Arreola L, Long T, Asarnow D, Suzuki BM, Singh R, Caffrey CR. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS ONE. 2014;9:e87594.","journal-title":"PLoS ONE."},{"key":"3747_CR23","doi-asserted-by":"publisher","first-page":"10873","DOI":"10.3390\/molecules200610873","volume":"20","author":"J Glaser","year":"2015","unstructured":"Glaser J, Schurigt U, Suzuki BM, Caffrey CR, Holzgrabe U. Anti-schistosomal activity of cinnamic acid esters: eugenyl and thymyl cinnamate induce cytoplasmic vacuoles and death in schistosomula of Schistosoma mansoni. Molecules. 2015;20:10873\u201383.","journal-title":"Molecules"},{"key":"3747_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/s41598-017-18457-w","volume":"8","author":"JC Weeks","year":"2018","unstructured":"Weeks JC, Roberts WM, Leasure C, Suzuki BM, Robinson KJ, Currey H, et al. Sertraline, paroxetine, and chlorpromazine are rapidly acting anthelmintic drugs capable of clinical repurposing. Sci Rep. 2018;8:975.","journal-title":"Sci Rep."},{"key":"3747_CR25","first-page":"3191","volume":"54","author":"JN Milligan","year":"2011","unstructured":"Milligan JN, Jolly ER. Cercarial transformation and in vitro cultivation of Schistosoma mansoni schistosomules. J Vis Exp. 2011;54:3191.","journal-title":"J Vis Exp."},{"key":"3747_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s00436-001-0511-5","volume":"88","author":"P M\u00e4ser","year":"2002","unstructured":"M\u00e4ser P, Grether-B\u00fchler Y, Kaminsky R, Brun R. An anti-contamination cocktail for the in vitro isolation and cultivation of parasitic protozoa. Parasitol Res. 2002;88:172\u20134.","journal-title":"Parasitol Res."},{"key":"3747_CR27","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1517\/17460441.2.S1.S53","volume":"2","author":"B Ramirez","year":"2007","unstructured":"Ramirez B, Bickle Q, Yousif F, Fakorede F, Mouries M-A, Nwaka S. Schistosomes: challenges in compound screening. Expert Opin Drug Discov. 2007;2:S53\u201361.","journal-title":"Expert Opin Drug Discov."},{"key":"3747_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13071-017-2240-3","volume":"10","author":"PHN Aguiar","year":"2017","unstructured":"Aguiar PHN, Fernandes NMGS, Zani CL, Mour\u00e3o MM. A high-throughput colorimetric assay for detection of Schistosoma mansoni viability based on the tetrazolium salt XTT. Parasites Vectors. 2017;10:300.","journal-title":"Parasites Vectors."},{"key":"3747_CR29","first-page":"4827","volume":"48","author":"DA Scudiero","year":"1988","unstructured":"Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium\/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48:4827\u201333.","journal-title":"Cancer Res."},{"key":"3747_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/jcc.540150503","volume":"15","author":"R Abagyan","year":"1994","unstructured":"Abagyan R, Totrov M, Kuznetsov D. ICM - a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J Comput Chem. 1994;15:488\u2013506.","journal-title":"J Comput Chem."},{"key":"3747_CR31","unstructured":"Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer; 2016. \n                    https:\/\/ggplot2.tidyverse.org\n                    \n                  . Accessed 2 Aug 2019."},{"key":"3747_CR32","doi-asserted-by":"publisher","first-page":"e0003484","DOI":"10.1371\/journal.pntd.0003484","volume":"9","author":"C Lalli","year":"2015","unstructured":"Lalli C, Guidi A, Gennari N, Altamura S, Bresciani A, Ruberti G. Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9:e0003484.","journal-title":"PLoS Negl Trop Dis."},{"key":"3747_CR33","doi-asserted-by":"publisher","first-page":"e759","DOI":"10.1371\/journal.pntd.0000759","volume":"4","author":"E Peak","year":"2010","unstructured":"Peak E, Chalmers IW, Hoffmann KF. Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect Schistosoma viability. PLoS Negl Trop Dis. 2010;4:e759.","journal-title":"PLoS Negl Trop Dis."},{"key":"3747_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijpddr.2015.07.002","volume":"5","author":"G Rinaldi","year":"2015","unstructured":"Rinaldi G, Loukas A, Brindley PJ, Irelan JT, Smout MJ. Viability of developmental stages of Schistosoma mansoni quantified with xCELLigence worm real-time motility assay (xWORM). Int J Parasitol Drugs Drug Resist. 2015;5:141\u20138.","journal-title":"Int J Parasitol Drugs Drug Resist."},{"key":"3747_CR35","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1128\/AAC.04601-14","volume":"59","author":"NC Fonseca","year":"2015","unstructured":"Fonseca NC, da Cruz LF, da Silva Villela F, do Nascimento Pereira GA, de Siqueira-Neto JL, Kellar D, et al. Synthesis of a sugar-based thiosemicarbazone series and structure\u2013activity relationship versus the parasite cysteine proteases Rhodesain, Cruzain, and Schistosoma mansoni Cathepsin B1. Antimicrob Agents Chemother. 2015;59:2666\u201377.","journal-title":"Antimicrob Agents Chemother."},{"key":"3747_CR36","doi-asserted-by":"publisher","first-page":"e0003962","DOI":"10.1371\/journal.pntd.0003962","volume":"9","author":"G Panic","year":"2015","unstructured":"Panic G, Vargas M, Scandale I, Keiser J. Activity profile of an FDA-approved compound library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9:e0003962.","journal-title":"PLoS Negl Trop Dis."},{"key":"3747_CR37","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1371\/journal.pntd.0000350","volume":"3","author":"J Keiser","year":"2009","unstructured":"Keiser J, Chollet J, Xiao S-H, Mei J-Y, Jiao P-Y, Utzinger J, et al. Mefloquine\u2014an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis. 2009;3:e350.","journal-title":"PLoS Negl Trop Dis."},{"key":"3747_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0166-6851(02)00031-2","volume":"121","author":"HM Alger","year":"2002","unstructured":"Alger HM, Williams DL. The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol Biochem Parasitol. 2002;121:129\u201339.","journal-title":"Mol Biochem Parasitol."},{"key":"3747_CR39","doi-asserted-by":"publisher","first-page":"28977","DOI":"10.1074\/jbc.M109.020701","volume":"284","author":"F Angelucci","year":"2009","unstructured":"Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, Dimastrogiovanni D, et al. Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin structural and kinetic aspects. J Biol Chem. 2009;284:28977\u201385.","journal-title":"J Biol Chem."},{"issue":"Suppl. 1","key":"3747_CR40","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/1471-2164-13-S1-S4","volume":"13","author":"H Lee","year":"2012","unstructured":"Lee H, Moody-Davis A, Saha U, Suzuki BM, Asarnow D, Chen S, et al. Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis. BMC Genomics. 2012;13(Suppl. 1):S4.","journal-title":"BMC Genomics."},{"key":"3747_CR41","doi-asserted-by":"crossref","unstructured":"Singh R, Pittas M, Heskia I, Xu F, McKerrow J, Caffrey CR. Automated image-based phenotypic screening for high-throughput drug discovery. In: 2009 22nd IEEE international symposium on computer-based medical systems; 2009. p. 1\u20138.","DOI":"10.1109\/CBMS.2009.5255338"},{"key":"3747_CR42","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s00436-011-2786-5","volume":"110","author":"HG Bert\u00e3o","year":"2012","unstructured":"Bert\u00e3o HG, da Silva RAR, Padilha RJR, de Azevedo Albuquerque MCP, R\u00e1dis-Baptista G. Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms. Parasitol Res. 2012;110:2465\u201373.","journal-title":"Parasitol Res."},{"key":"3747_CR43","doi-asserted-by":"publisher","first-page":"e0141788","DOI":"10.1371\/journal.pone.0141788","volume":"10","author":"MM Eissa","year":"2015","unstructured":"Eissa MM, El-Moslemany RM, Ramadan AA, Amer EI, El-Azzouni MZ, El-Khordagui LK. Miltefosine lipid nanocapsules for single dose oral treatment of schistosomiasis mansoni: a preclinical study. PLoS ONE. 2015;10:e0141788.","journal-title":"PLoS ONE"},{"key":"3747_CR44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijpara.2010.09.010","volume":"41","author":"MM Eissa","year":"2011","unstructured":"Eissa MM, El-Azzouni MZ, Amer EI, Baddour NM. Miltefosine, a promising novel agent for schistosomiasis mansoni. Int J Parasitol. 2011;41:235\u201342.","journal-title":"Int J Parasitol."},{"key":"3747_CR45","doi-asserted-by":"publisher","first-page":"e0005853","DOI":"10.1371\/journal.pntd.0005853","volume":"11","author":"MH El-Faham","year":"2017","unstructured":"El-Faham MH, Eissa MM, Igetei JE, Amer EI, Liddell S, El-Azzouni MZ, et al. Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens. PLoS Negl Trop Dis. 2017;11:e0005853.","journal-title":"PLoS Negl Trop Dis."},{"key":"3747_CR46","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1017\/S003118201000065X","volume":"137","author":"FFB Couto","year":"2010","unstructured":"Couto FFB, Coelho PMZ, Araujo N, Kusel JR, Katz N, Mattos ACA. Use of fluorescent probes as a useful tool to identify resistant Schistosoma mansoni isolates to praziquantel. Parasitology. 2010;137:1791\u20137.","journal-title":"Parasitology."}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3747-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13071-019-3747-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-019-3747-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:29:52Z","timestamp":1603236592000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-019-3747-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3747"],"URL":"https:\/\/doi.org\/10.1186\/s13071-019-3747-6","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"12 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We acknowledge the MMV for designing and supplying the Pathogen Box. Vertebrate maintenance and handling at the UCSD Animal Care Facility were in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at UCSD. The procedures involving laboratory animals at the Swiss TPH were approved by the Canton of Basel-Stadt and met the ethical standards set both by the cantonal and Swiss veterinary authorities (license no. 2070). They were also performed according to the 3Rs principles (). At FIOCRUZ, the experiments involving laboratory animals were carried out according to Brazilian national guidelines for the use of animals in scientific research. Animal experiments carried out for this report were approved by the Ethics Commission for Animal Use (CEUA) under the license number LW-32\/17.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"493"}}